{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:57:59Z","timestamp":1771261079063,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bbmt.2016.07.010","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T15:38:57Z","timestamp":1469201937000},"page":"1816-1822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Scott R.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie A.","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.07.010_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2000.02196.x","article-title":"Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0015","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0020","first-page":"242","article-title":"Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience","volume":"3","author":"Shimoni","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0025","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0030","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0040","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0070","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0075","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813","article-title":"Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation","volume":"86","author":"Gratwohl","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0090","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703260","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0100","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2008-07-168625","article-title":"Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison","volume":"113","author":"Cornelissen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0105","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0110","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0115","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system","volume":"29","author":"Rollig","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0120","first-page":"13","article-title":"Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time\u2014a report of the Acute Leukemia Working Party of the European Group for Blood And Marrow Transplantation (EBMT)","volume":"17","author":"Frassoni","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1046\/j.1365-2141.2002.03532.x","article-title":"Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry","volume":"117","author":"Greinix","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.bmt.1700761","article-title":"Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Societe Francaise de Greffe de Moelle (SFGM)","volume":"19","author":"Jourdan","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0140","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0145","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1083-8791(03)00149-6","article-title":"Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia","volume":"9","author":"Doney","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0150","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0155","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0160","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bmt.2013.66","article-title":"In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study","volume":"48","author":"Aristei","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0165","first-page":"232","article-title":"Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome","volume":"90","author":"De Souza","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.thj.6200117","article-title":"Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants","volume":"2","author":"Gratwohl","year":"2001","journal-title":"Hematol J"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.tp.0000226156.99206.d1","article-title":"Influence of donor\/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia","volume":"82","author":"Stern","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0180","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","article-title":"A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation","volume":"112","author":"Ciceri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0185","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0190","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0195","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1200\/JCO.2005.02.5940","article-title":"Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience","volume":"23","author":"Jourdan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0200","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0205","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0210","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","article-title":"Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial","volume":"104","author":"Hunault","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0215","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.21932","article-title":"Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis","volume":"106","author":"Yanada","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0220","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0225","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0230","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0235","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1704865","article-title":"How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!","volume":"35","author":"Heemskerk","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0245","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bmt.2012.150","article-title":"Race\/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0250","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3324\/haematol.2011.041004","article-title":"Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial","volume":"96","author":"Stelljes","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0255","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbmt.2013.10.023","article-title":"Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission","volume":"20","author":"Warlick","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.07.010_bib0260","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/cncr.28498","volume":"120","author":"Yeshurun","year":"2014","journal-title":"Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116302464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T17:45:25Z","timestamp":1656870325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116302464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1083879116302464"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.010","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}